systolic thickening ratio (ratio of RVM end-systole/end-diastole thickness) showed AUC of 0.540, 0.489, 0.699, 0.634, respectively, best cutoff points of 73HU (sensitivity 81%, specificity 41%), 91HU (sensitivity 42%, specificity 69%), 3.55mm (sensitivity 50%, specificity 83%), and 1.47 (sensitivity 69%, specificity 69%), respectively, to distinguish subjects with/without RV asynergy. By Kaplan Meier analysis, adverse events were more frequent in subjects with RV wall asynergy on CT than in those without (P=0.041). Conclusions: Quantitative and qualitative morphological and functional parameters of RVM on 4D images of ECG gated 320 slice CT have relationship to RV wall asynergy which can predict short term poor prognosis in PH subjects.
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Long term prognosis value of coronary computed tomography angiography in patients with normal coronary arteries D. Casagrande 1 , J.J. Goy 1 , L. Poncioni 2 , R. Androux 2 , S. Cook 1 . 1 Cantonal Hospital, Fribourg, Switzerland; 2 Clinique Cecil, Lausanne, Switzerland Purpose: Use of Computed Tomography Angiography (CTA) is increasing in patients with suspected coronary artery disease (CAD). Although there is a large body of data supporting the prognostic role of CTA for major adverse cardiac events in the short and intermediate term, its long-term prognostic role in patients with normal coronary arteries is still largely unknown. The aim of this study was to assess the 5 year prognostic of multidetector computed tomography coronary angiography in patients with normal coronary arteries. Methods: Between January 2004 and June 2006, 506 consecutive patients (313 men and 197 women) were investigated with CTA for detecting the presence of coronary artery disease. Patients were classified according to their coronary status as normal coronary arteries and abnormal (plaques, calcified and obstructive coronary arteries). The composite endpoint was rates of cardiac events (cardiac deaths, nonfatal myocardial infarctions, acute coronary syndrome and stable angina pectoris) and all cardiac events. The first 200 consecutive patients with strictly normal coronary arteries (124 men and 76 women) with a mean age of 64±27 years were prospectively included in the registry. They were followed for exactly 5 years after the initial investigation. Background: Aortic valve stenosis (AVS) is the most common valvular heart disease in the Western world, and may share some risk factors with coronary heart disease (CHD). Clinical trials have failed to show a benefit for statin therapy in delaying the progression of AVS among asymptomatic individuals with known AVS. Whether statin therapy may decrease the incidence of AVS in populations enriched with CHD risk factors is unknown. Our objective was to compare the incidence rates of AVS among patients treated with high-versus low-dose statin or placebo and to identify clinical risk factors associated with the risk of AVS. Methods and results: Results from three large-scale atorvastatin trials were included in this study, the Treating to New Targets (TNT) trial, in which 80 mg and 10 mg/day of atorvastatin were compared in patients with stable coronary disease, the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) trial, in which atorvastatin 80 mg was compared to simvastatin 20 mg/day in post-myocardial infarction patients, and the Stroke Prevention by Aggressive Reduction in Cholesterol levels (SPARCL) trial, in which 80 mg/day of atorvastatin was compared to placebo in patients with a recent stroke or transient ischemic attack. All patients with known AVS at baseline were excluded from this analysis. During the follow-up (median=4.9 years), 45 patients developed AVS in TNT, 28 in IDEAL and 9 in SPARCL. Among the 82 patients who developed AVS, 39 (47.6%) patients were treated with atorvastatin 80 mg and 43 (52.4%) were treated with low-dose statin or placebo (hazard ratio [HR]=0.91 [95% CI, 0.59-1.41], p=0.67). Risk factors that showed a significant association in univariate regression analyses were entered into a multivariate model. These risk factors included age, height, weight, body mass index, diabetes, angina, previous coronary artery bypass grafting, peripheral vascular disease, warfarin and antiplatelets use, prior use of statins and calcium channel blockers use. In multivariate analyses forcing treatment, sex and race into the model, age (hazard ratio [HR]=2.24 [95% CI, 1.66-3.02], p<0.0001 per 1-SD increment), diabetes (HR=1.69 [1.00-2.82], p=0.05), warfarin and antiplatelets use (HR=2.89 [1.80-4.62], p<0.0001) and prior statin use (HR=2.56 [1.48-4.44], p=0.03) were significantly associated with the onset of AVS. Conclusions: In this study, high-dose statin therapy did not impact the incidence of AVS. We found that age, diabetes, warfarin and antiplatelets use and prior use of statins were significant predictors of incident AVS in these high-risk patients.
Results
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A prospective, double-blinded, randomized trial of Ramipril in asymptomatic aortic stenosis: the RIAS trial Background: Angiotensin-converting-enzyme (ACE) inhibitors have potential benefit through positive remodeling in aortic stenosis (AS) but no prospective clinical trials have been carried out. We hypothesized that ramipril would lead to regression of LV mass in patients with AS and potentially slow disease progression. Methods: We conducted a prospective, randomized, double-blind, placebocontrolled trial focusing on cardiac physiology. 100 patients with moderate or severe asymptomatic AS were randomized to either ramipril 10mg daily (n=50) or placebo (n=50) for a year. Patients underwent assessment at baseline, six and twelve months, consisting of CMR scanning to determine LV mass, function, strain, perfusion and T1 values; echocardiography and exercise testing.
Results: Data was available in 78 patients for the primary endpoint (LV mass) at 12 months. There was a reduction in LV mass in the ramipril group (mean change ±standard deviation: -2.0±1.7g at 6 months; -3.9±2.1g at 12 months, compared to an increase in LV mass in the placebo group: +2.0±1.5g at 6 months; +4.5±2.0g at twelve months (mean difference at 12 months 8.4g [5%]; p=0.006; Figure 1 ). There was a trend towards reduction in valve area (-0.2cm 2 , p=0.067) and increase in peak aortic velocity (+0.1m/sec, p=0.056) in the placebo group, and fewer deaths in the ramipril group after completion of the trial (p= 0.074).
Change from baseline in LV Mass
Conclusion: Ramipril is safe in moderate and severe asymptomatic AS and leads to a small but significant reduction in LV mass at 12 months. There were trends towards slower progression of valvular stenosis and fewer deaths post-trial in the treatment group. A larger multi-center clinical outcome trial over a longer period is required to determine whether this translates into clinical benefit. Purpose: Patients with severe aortic stenosis (AS) and paradoxical low flow (PLF) (indexed stroke volume< 35ml/m 2 ) despite preserved left ventricular ejection fraction >50%, have worse outcome compared to those with AS but normal flow. Moreover, Prosthesis-Patient Mismatch (PPM) (indexed prosthetic valve effective orifice area< 0.85cm 2 /m 2 ) after aortic valve replacement (AVR) is a predictor of higher mortality. However, the impact of PPM in patients with PLFAS on long-term survival is unknown. Our aim was to analyze the prevalence and the impact on long-term survival of PPM in patients with PLFAS. Methods: 667 consecutive patients (age 74±8 years, 42% female, AVA 0.69±0.16 cm 2 ) with preserved LVEF who underwent AVR for severe AS at our institution between 2000 and 2010 were included in this study. Patients were divided into 4 groups according to the presence/absence of PLF at cardiac catheterization and presence/absence of PPM following AVR and we compared short and long-term survival between these groups. Results: Among the 667 patients, 26% had PLFAS and PPM occurred in 54% of patients after AVR. Compared to patients with no PLF & no PPM (36% of the total cohort), those with PLF & PPM (15%) were significantly older, with more comorbidities. The 30-day mortality did not differ between the PLF-PPM and no-PLF-no PPM group. The 10-yr survival rate was significantly reduced in the PLF-PPM (37±9%) group compared to no PLF-no PPM (70±5%; p=0.003). In multivariate analysis adjusting for all predictors of survival, concomitant presence 10-year survival according to PPM/PLF of PLF & PPM was an independent predictor of survival (HR= 2.68 95% CI: 1.5-4.4; p=0.0003) Conclusion: In this catheterization-based study, patients with PLF and PPM have worse outcome when compared to those without these 2 conditions.
P4718 | BEDSIDE
Prevalence and impact of prosthesis-patient mismatch in patients with paradoxical low-flow severe aortic stenosis
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Echocardiographic evaluation of severe aortic stenosis: impact of three-dimensional imaging and correction for pressure recovery B.E. Staehli, A. Abouelnour, A. Vecchiati, R. Jenni, F.C. Tanner. Cardiology, Cardiovascular Center, University Hospital Zürich, Zurich, Switzerland Purpose: In patients with Aortic Stenosis (AS), echocardiographic grading of stenosis severity is important, in particular when valve surgery or Transcatheter Aortic Valve Implantation (TAVI) are considered. Energy Loss Index (ELI) has been proposed to improve the determination of aortic valve area (AVA) by correcting for the effects of pressure recovery. However, the impact of ELI on calculation of AVA in patients with severe AS has not been studied, and the effect of 3D echocardiography in this context is not known. Methods: Transthoracic (TTE) and Transesophageal (TEE) echocardiography studies of 40 patients (54% males) with severe AS evaluated for TAVI were analyzed. AVA was calculated by the continuity equation based on Left Ventricular Outflow Tract (LVOT) diameter measured in 2D-TTE and 2D-TEE as well as based on LVOT area measured in 3D-TEE. In addition, AVA determined by 3D-TEE measurements was corrected for ELI (ELI = [(AVA × Aortic area)/Aortic area -AVA)]/body surface area). AVA and indexed AVA (AVAI) obtained from these four methods were compared. Results: LVOT area was 2.45±0.91 cm 2 calculated using 2D-TTE diameter measurements, 2.82±0.78 cm 2 calculated using 2D-TEE diameter measurements, and 4.27±0.89 cm 2 measured in 3D-TEE (p<0.001). The AVA was 0.52±0.19 cm 2 calculated using 2D-TTE values, 0.59±0.17 cm 2 using 2D-TEE values, and 0.90±0.22 cm 2 using 3D-TEE values (p<0.001). The AVAI calculated by 2D-TTE and 2D-TEE was smaller (0.29±0.11 cm 2 /m 2 and 0.33±0.10 cm 2 /m 2 , respectively) as compared to the value obtained by 3D-TEE (0.51±0.13 cm 2 /m 2 ; p<0.001). When AVAI assessed by 3D-TEE was corrected for pressure recovery by ELI, there was a further increase (0.60±0.17 cm 2 /m 2 ; p<0.001). Utilizing 3D-TEE and correction for pressure recovery by ELI, 40% of patients were reclassified to have moderate aortic stenosis with an AVAI between 0.60-0.85 cm 2 /m 2 , and 2 patients had AVAI >0.85 cm 2 /m 2 . Conclusions: Since the true LVOT is not circular, the geometric assumptions used for calculation of AVAI from 2D measurements lead to underestimation of AVA in patients with severe AS. The effects of pressure recovery accentuate this problem. When both the true LVOT area and the effects of pressure recovery are considered, AS needs to be reclassified from severe to moderate in over a third of patients. The implementation of these parameters in echocardiographic practice might improve the accuracy of AS severity assessment.
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Current echocardiography guidelines have serious limitations in patients with aortic regurgitation: an echocardiography and cardiovascular magnetic resonance study
S. Gao 1 , C.L. Polte 1 , K. Lagerstrand 1 , U. Cederbom 2 , O. Bech-Hanssen 1 . 1 Sahlgrenska University Hospital, Gothenburg, Sweden; 2 Norra Alvsborgs Hospital, Trollhattan, Sweden Purpose: Current echocardiography guidelines on grading of aortic regurgitation (AR) define cut-off levels for six different parameters in favour of severe regurgitation (major criteria). The purpose of the study was to evaluate the feasibility and applicability in clinical practice of these parameters and cut-off levels. Methods: In this prospective study we performed echocardiography and cardiovascular magnetic resonance (CMR) on the same day in 20 patients with AR prior to aortic valve surgery. The echocardiography parameters included vena contracta width (VC), pressure half time (PHT), effective regurgitant orifice area (EROA), regurgitant volume (RVecho), left ventricular diastolic volume index (LVDVI) and end-diastolic velocity of flow reversal in descending aorta (Vdesc). Results: The mean ± SD age was 52±13 years and two were women. Surgery was indicated due to symptomatic AR (90%) or significant left ventricular dilatation (10%). The median (25 to 75% percentile) of RVcmr was 82 ml (60 to 123 ml). All 6 parameters were possible to obtain in only 55% of the patients, whereas ≤ 3 parameters were obtained in 35% of the patients. There was a significant correlation between number of major criteria and RVcmr (r=0.75, P<0.0001). Thirty-five percent of the patients fulfilled ≥ 3, whereas 30% fulfilled ≤1 of major criteria. The LVDVI and Vdesc were most feasible and the correlation to RVcmr was strong 
